Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
- 作者W. J. Sandborn; B. E. Sands; D. C. Wolf; J. F. Valentine; M. Safdi; S. Katz; K. L. Isaacs; L. D. Wruble; J. Katz; D. H. Present; E. V. Loftus JR; F. Graeme-Cook; D. J. Odenheimer; S. B. Hanauer
- 卷第17卷
- 期第11期
- 印刷ISSN0269-2813
- 电子ISSN1365-2036
- 文件大小90.86KB
- 发表时间2003
- DOI10.1046/j.1365-2036.2003.01589.x
- 页码1355-1364
<i>Dillenia</i> species: A review of the traditional uses, active constituents and pharmacological properties from pre-clinical studiesSaiful Yazan, Latifah; Armania, Nurdin · Pharmaceutical Biology · 2014
Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren’s SyndromeDr Hiroshi Yasuda, Hiroshi Niki · 2002
Erratum to Epoetin beta: a review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failureC. J. Dunn,A. Markham · Drugs · 1996
Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) TuberculosisDartois, Veronique; E. Barry, Clifton · Current Clinical Pharmacology · 2010